Akouos (Akouos) Momentum Rank : 0 (As of May. 05, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Akouos Momentum Rank?

Akouos has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Akouos Momentum Rank Related Terms

Thank you for viewing the detailed overview of Akouos's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Akouos (Akouos) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akouos Inc (NAS:AKUS) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

645 Summer Street, Suite 200, Boston, MA, USA, 02210

Website

https://www.akouos.com

Akouos Inc is a genetic medicine company focused on developing gene therapies that restore, improve, and preserve hearing. The company is involved in developing potential genetic medicines for a variety of inner ear disorders.

Executives

Kearny Acquisition Corp	10 percent owner	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Lilly Eli & Co	10 percent owner	LILLY CORPORATE CENTER, DROP CODE 1094, INDIANAPOLIS IN 46285
Jennifer Anne Wellman	officer: Chief Operating Officer	C/O AKOUOS, INC., 645 SUMMER STREET, SUITE 200, BOSTON MA 02210
Sachiyo Minegishi	officer: Chief Financial Officer	C/O AKOUOS, INC., 645 SUMMER STREET, SUITE 200, BOSTON MA 02210
5am Ventures V, L.p.	10 percent owner	2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025
Kush Parmar	director, 10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Carmen Chang	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Maha Katabi	10 percent owner	SOFINNOVA INVESTMENTS, 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Sofinnova Venture Partners X, L.p.	10 percent owner	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Pivotal Bioventure Partners Fund I G.p., L.p.	10 percent owner	501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107
New Enterprise Associates 16, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Paul Edward Walker	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Heather Preston	director, 10 percent owner	C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, FORT WORTH TX 76102